Autopsy report · NCT01071902

Safety and Efficacy of Moxidex Otic

“Management decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 8 months before it stopped.
• 400 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Alcon Research

Sponsor type

Industry

Conditions

Acute Otitis Media

Interventions

Moxidex otic solution; Moxifloxacin otic solution; Vehicle; Tympanostomy tubes

Participants

400

Sites

1

Countries

United States

Trials that died the same way

• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
  “Business decision” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.